Thyroid diseases, dyslipidemia and cardiovascular risk

Česká verzia

Authors: J. Jiskra; Z. Límanová; M. Antošová
Authors place of work: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2007; 53(4): 382-385
Category: Reviews

Summary

By affecting the metabolism of lipids, hypothyroidism accelerates the process of atherogenesis and increases cardiovascular risk. In manifest hypothyroidism the number of LDL receptors in the liver decreases and there is an increase in levels of overall cholesterol, LDL-cholesterol and apolipoprotein B in the blood. Levels of HDL particles remain normal or even rise slightly as a result of reduced activity of the Cholesterol ester transfer protein (CETP) and hepatic lipase. This leads to a reduction in the transport of cholesterol esters from HDL-(2) to VLDL and IDL. Subclinical hypothyroidism also has a negative effect on the lipid profile, but is more likely to lead to pro-atherogenic changes in the proportion of lipid particles than to a reduction in overall cholesterol. subclinical hypothyroidism leads to the manifestation of certain risk factors of atherosclerosis. Although studies of overall mortality and cardiovascular morbidity have not been completely unanimous in their conclusions, increased cardiovascular risk can be considered likely in subclinical hypothyroidism. It remains an open question whether the treatment of subclinical hypothyroidism with levothyroxine. At present we have only indirect proof from studies that assessed the effect of levothyroxine treatment on risk factors of atherosclerosis. Starting treatment with lipid lowering agents (especially statins) for (sub)clinical hypothyroidism is extremely risky though due to the risk of the development or worsening of myopathy, which is a further cogent argument for the active screening and treatment of (sub)clinical hypothyroidism for all patients with dyslipidemia.

Key words:
subclinical hypothyroidism – TSH – cholesterol – LDL-cholesterol – cardiovascular risk

Zdroje

1. Mayer O Jr, Šimon J, Hrbková J et al. Epidemiologická studie hypotyreózy jako kardiovaskulárního rizika v populaci. Čas Lék Česk 2005; 144: 459-464.

2. Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287-293.

3. Luboshitzky R, Aviv A, Herer P et al. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12: 421-425.

4. Walsh JP, Bremner AP, Bulsara MK et al. Thyroid dysfunction and serum lipids: a community-based study. Clin Endocrinol (Oxf) 2005; 63: 670-675.

5. Tanaci N, Ertugrul DT, Sahin M et al. Postprandial lipemia as a risk factor for cardiovascular disease in patients with hypothyroidism. Endocrine 2006; 29: 451-456.

6. Hamano K, Inoue M. Increased risk for atherosclerosis estimated by pulse wave velocity in hypothyroidism and its reversal with appropriate thyroxine treatment. Endocr J 2005; 52: 95-101.

7. Nagasaki T, Inaba M, Kumeda Y et al. Increased pulse wave velocity in subclinical hypothyroidism. J Clin Endocrinol Metab 2006; 91: 154-158.

8. Lekakis J, Papamichael C, Alevizaki M et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997; 7: 411-414.

9. Dagre AG, Lekakis JP, Protogerou AD et al. Abnormal endothelial function in female patients with hypothyroidism and borderline thyroid function. Int J Cardiol 2007; 114: 332-338.

10. Owecki M, Michalak A, Nikisch E et al. Subclinical hypothyroidism influences ventricular repolarization measured by QTc interval. Przegl Lek 2006; 63: 185-187.

11. Monzani F, Di Bello V, Caraccio N et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab 2001; 86: 1110-1115.

12. Aghini-Lombardi F, Di Bello V, Talini E et al. Early textural and functional alterations of left ventricular myocardium in mild hypothyroidism. Eur J Endocrinol 2006; 155: 3-9.

13. Series JJ, Biggart EM, O’Reilly DS et al. Thyroid dysfunction and hypercholesterolaemia in the general population of Glasgow, Scotland. Clin Chim Acta 1988; 172: 217-221.

14. Bindels AJ, Westendorp RG, Frolich M et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Clin Endocrinol (Oxf) 1999; 50: 217-220.

15. Límanová Z, Fiedler J, Češka R. Are thyroid function disturbances correctly diagnosed before hypolipidemic drugs administration? The Thyroid Gland 2000; 1: 19-27.

16. Zamrazil V. Vliv věku na štítnou žlázu. Diabetes Metabolismus Endokrinologie Výživa 2001; 1: 46-52.

17. Vrablík M. Co víme o sekundárních dyslipidémiích? Medicína po promoci 2004; 5: 9-73.

18. Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemia. Ann Fam Med 2004; 2: 351-355.

19. Mayer O Jr, Šimon J, Filipovský J et al. Hypothyroidism in coronary heart disease and its relation to selected risk factors. Vasc Health Risk Manag 2006; 2: 499-506.

20. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of diabetes mellitus in an English community: a 20-year follow-up of the Whickham Survey. Diabet Med 1996; 13: 741-747.

21. Cappola AR, Fried LP, Arnold AM et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295: 1033-1041.

22. Hak AE, Pols HA, Visser TJ et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132: 270-278.

23. Walsh JP, Bremner AP, Bulsara MK et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165: 2467-2472.

24. Rodondi N, Newman AB, Vittinghoff E et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; 165: 2460-2466.

25. Rodondi N, Aujesky D, Vittinghoff E et al. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med 2006; 119: 541-551.

26. Meier C, Staub JJ, Roth CB et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86: 4860-4866.

27. Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. J Intern Med 2006; 260: 53-61.

28. Razvi S, Ingoe L, Keeka G et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in subclinical hypothyroidism: randomised, crossover trial. J Clin Endocrinol Metab 2007; Epub ahead of print.

29. Singer RB. Mortality in a complete 4-year follow up of 85-year-old residents of Leiden, classified by serum level of thyrotropin and thyroxine. J Insur Med 2006; 38: 14-19.

30. Jiskra J. Změny svalové tkáně při hypotyreóze. Vnitř Lék 2001; 47: 609-612.

31. Beyer IW, Karmali R, Demeester-Mirkine N et al. Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid 1998; 8: 1029-1031.

32. Češka R et al. Cholesterol a ateroskleróza, léčba dyslipidemií. Praha: Triton 2005: 72-73.

33. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53(2): 181-197.